Priya Patel working as an Assistant Professor, Dept., of Pharmaceutical Sciences, Saurashtra University Rajkot. Having 5.5 years of teaching and research experience. Core Area of interest is Cancer Nanotechnology and Novel drug delivery system. Received grant from GUJCOST Worth Rs. 6,20,000/- For MRP on Cancer Nanotechnology and Rs. 50,000/- for organizing a one-day national seminar on cancer Nano formulation. Received travel grant from DBT, CSIR WorthRs. 82,000 and 30,000 respectively. Guided 9 master’s students for their research work. Also got proze in various national and international paper presentations.
Among various diseases, cancer has become a big threat to human beings globally. In worldwide, more than 80% of people having a habit of smoking, hence among various cancers Lung cancer have more chances as compared to other cancer. Lung cancer accounts for about 47% of all cancer deaths and is by far the leading cause of cancer death among both men and women. Considering the challenges associated with conventional chemotherapy, targeted and local delivery of chemotherapeutics via nanoparticle (NP) carriers to the lungs is an emerging area of interest. Recent studies and growing clinical application in cancer nanotechnology showed the huge potential of NPs as drug carriers in cancer therapy, including in lung carcinoma for diagnosis, imaging, and theranostics. Researchers have confirmed that nanotechnology-based inhalation chemotherapy with specific targeting is viable and more effective than conventional chemotherapy, with lesser side effects. Recently, many nanocarriers have been investigated, including polymeric micelles, liposomes, polymeric NPs and solid lipid NPs for inhalation treatments of lung cancer. Yet, the toxicity of such nanomaterials to the lungs tissues and further distribution to other organs due to systemic absorption on inhalation delivery is a debatable concern.